Table of Contents Author Guidelines Submit a Manuscript

An erratum for this article has been published. To view the erratum, please click here.

Journal of Biomedicine and Biotechnology
Volume 2007 (2007), Article ID 13684, 9 pages
Research Article

Investigation of Microencapsulated BSH Active Lactobacillus in the Simulated Human GI Tract

1Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, 3775 University Street, Montreal, PQ, Canada H3A 2B4
2Department of Physiology, Faculty of Medicine, McGill University, 3655 Promenade Sir William Osler, Montreal, PQ, Canada H3G 1Y6
3Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Montreal, PQ, Canada H3G 1Y6

Received 15 May 2007; Accepted 7 October 2007

Academic Editor: Allal Ouhtit

Copyright © 2007 Christopher Martoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study investigated the use of microencapsulated bile salt hydrolase (BSH) overproducing Lactobacillus plantarum 80 cells for oral delivery applications using a dynamic computer-controlled model simulating the human gastrointestinal (GI) tract. Bile salt deconjugation rates for microencapsulated BSH overproducing cells were 4.87 ± 0.28 μmol/g microcapsule/h towards glycoconjugates and 0.79 ± 0.15 μmol/g microcapsule/h towards tauroconjugates in the simulated intestine, a significant (P< .05) increase over microencapsulated wild-type cells. Microcapsules protected the encased cells in the simulated stomach prior to intestinal release, maintaining cell viability above 109 cfu/mL at pH 2.5 and 3.0 and above 106 cfu/mL at pH 2.0 after 2-hour residence times. In the simulated intestine, encased cell viability was maintained above 1010 cfu/mL after 3, 6, and 12-hour residence times in bile concentrations up to 1.0%. Results show that microencapsulation has potential in the oral delivery of live BSH active bacterial cells. However, in vivo testing is required.